Alimera Sciences (ALIM) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12 month target prices for Alimera Sciences' shares. Their ALIM share price forecasts range from $4.50 to $8.00. On average, they anticipate the company's stock price to reach $5.83 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price.
View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts.

Alimera Sciences' stock was trading at $2.71 at the beginning of 2023. Since then, ALIM shares have decreased by 2.6% and is now trading at $2.64.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our ALIM earnings forecast.

Alimera Sciences, Inc. (NASDAQ:ALIM) issued its earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.08. The biopharmaceutical company earned $12.15 million during the quarter, compared to analyst estimates of $12.30 million. During the same quarter in the prior year, the firm earned ($0.12) EPS.

Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALIM stock can currently be purchased for approximately $2.64.

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $19.54 million and generates $54.13 million in revenue each year. The biopharmaceutical company earns $-18,110,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

The company employs 145 workers across the globe.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.